NovoCure Ltd. (NVCR)

91.37
NASDAQ
Prev Close 91.07
Day Low/High 89.40 / 93.67
52 Wk Low/High 90.95 / 232.76
Exchange NASDAQ
Shares Outstanding 103.82B
Market Cap 9.45B
P/E Ratio 890.00
Div & Yield N.A. (N.A)

Latest News

Novocure Enters a New 'Phase'

Novocure Enters a New 'Phase'

Here is where aggressive traders could go long the cancer therapy name.

Charting NovoCure's Meteoric Stock Price Rise

Charting NovoCure's Meteoric Stock Price Rise

NVCR gapped sharply higher today, in one of the most impressive upside gaps we have seen in a long time. Check it out.

NovoCure Has Broken Down on the Charts: What to Do Now

NovoCure Has Broken Down on the Charts: What to Do Now

Our latest analysis and trading strategy on NVCR.

NovoCure Could Weaken Further in the Days Ahead

NovoCure Could Weaken Further in the Days Ahead

Let's check out the charts and indicators again.

How to Play NovoCure Stock Right Now

How to Play NovoCure Stock Right Now

Let's check out the charts and indicators again to see what has changed in the past month.

NovoCure Surges to New Highs: Here's the Technical Road Ahead

NovoCure Surges to New Highs: Here's the Technical Road Ahead

Prices have doubled in just three months.

50-Day Line in the Sand, Don't Blame Powell, Crude Awakening: Market Recon

50-Day Line in the Sand, Don't Blame Powell, Crude Awakening: Market Recon

Plus, the chart of Novocure Limited is a real attention-grabber while the chart of Apple bears watching.

7 High-Tech Winners in Medical Diagnostics and Devices

7 High-Tech Winners in Medical Diagnostics and Devices

These names combine healthcare research with state-of-the art technology.

Raise Stops on NovoCure

Raise Stops on NovoCure

NVCR's prices are poised to head higher in the months ahead.

NovoCure Looks Ready to Resume Its Strong Uptrend After a Correction

NovoCure Looks Ready to Resume Its Strong Uptrend After a Correction

Let's review the charts and indicators of NVCR.

Novocure's Charts Are as Bullish As They Get, So Here's My Strategy

Novocure's Charts Are as Bullish As They Get, So Here's My Strategy

The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.

NovoCure Looks Due for a Technical Correction

NovoCure Looks Due for a Technical Correction

Let's look at the charts and indicators in addition to following the fundamentals.

Upgrades, Downgrades, Initiations

Here we go folks, a sampling of this morning's upgrades, downgrades and initiations. I'll be back with some thought on these after I get another cup of my morning fuel (coffee).  Upgrades Sprint by UBS from Neutral to Buy with a $10 price target Res...

Novocure Could Climb Even Further; Here's Where to Buy

Novocure Could Climb Even Further; Here's Where to Buy

The oncology company already has risen significantly this year, but its charts indicate the rally could continue.

NovoCure's Charts Look Bullish

NovoCure's Charts Look Bullish

NovoCure started a strong rally in 2017 and continues to move up.

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Rev's Forum: Adapt to a Challenging Market Environment

Rev's Forum: Adapt to a Challenging Market Environment

The normal chart patterns don't operate like they have in the past.

Shark Bites: Focus on the 'Little Picture'

Shark Bites: Focus on the 'Little Picture'

Here's what I'm trading today amid the 'flat with a positive tone' action.

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Coming off a brutal first quarter, Bill Ackman's hedge fund announced the loss of a key strategist.

NovoCure Debuts on Nasdaq, Despite Weakness in IPO Market

NovoCure Debuts on Nasdaq, Despite Weakness in IPO Market

Cancer treatment company NovoCure (NVCR) debuted as a public company trading on the Nasdaq on Friday, despite weakness seen in the IPO market so far this year.

September Job Growth a Big Disappointment, U.S. Stocks Open Lower

September Job Growth a Big Disappointment, U.S. Stocks Open Lower

U.S. stocks opened lower Friday as the Labor Department stunned Wall Street with a majorly disappointing September jobs report.